体外循环后鱼精蛋白最佳剂量:PRODOSE适应性随机对照试验
该两阶段适应性随机对照试验将228例体外循环患者按数学模型或固定比例(每100 IU肝素配1 mg鱼精蛋白)给予鱼精蛋白,模型组kaolin TEG r-time更短且鱼精蛋白剂量更低,但术后引流量和输血需求无差异。
要点
- 基于肝素清除两室模型的鱼精蛋白给药可改善体外循环后TEG r-time。
- 模型组鱼精蛋白剂量中位数180 mg,低于固定比例组的280 mg。
- 术后4小时引流量和24小时红细胞输注需求两组无显著差异。
核心结论
- 使用数学模型指导体外循环后鱼精蛋白给药可改善TEG r-time并减少给药剂量。
- 在低风险患者中未检测到术后纵隔/胸膜引流量或红细胞输注需求的差异。
研究设计与样本
- 两阶段适应性随机对照试验,纳入228例体外循环患者。
- 干预组121例按肝素清除数学模型给药,对照组107例按固定比例(每100 IU肝素配1 mg鱼精蛋白)给药。
- 主要终点为体外循环结束时鱼精蛋白给药后3分钟kaolin TEG r-time。
主要发现
- 模型组体外循环后平均kaolin r-time为6.58(SD 2.50)分钟,对照组为8.08(SD 3.98)分钟,p=0.0016。
- 模型组鱼精蛋白后TEG更接近体外循环前参数,kaolin r-time比值中位数0.96(IQR 0.78-1.14) vs 0.75(IQR 0.57-0.99),p<0.001。
- 术后4小时纵隔/胸膜引流量中位数140(IQR 75-245) vs 135(IQR 94-222)mL,p=0.85。
- 术后24小时浓缩红细胞输注比例19例(15.8%) vs 14例(13.1%),p=0.69。
- 模型组鱼精蛋白剂量中位数180(IQR 160-210)mg,对照组280(IQR 250-300)mg,p<0.001。
临床怎么用
- 对体外循环后低风险患者,可考虑基于肝素清除数学模型给予鱼精蛋白以改善凝血指标并减少剂量。
- 该策略未显示减少术后引流或输血需求,临床决策需结合个体情况。
局限性
- 研究为未盲法设计。
- 结果不能推广至儿童、体重>120 kg或需治疗性低温至<28°C的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The dose of protamine required following cardiopulmonary bypass (CPB) is often determined by the dose of heparin required pre-CPB, expressed as a fixed ratio. Dosing based on mathematical models of heparin clearance is postulated to improve protamine dosing precision and coagulation. We hypothesised that protamine dosing based on a 2-compartment model would improve thromboelastography (TEG) parameters and reduce the dose of protamine administered, relative to a fixed ratio. METHODS AND FINDINGS: We undertook a 2-stage, adaptive randomised controlled trial, allocating 228 participants to receive protamine dosed according to a mathematical model of heparin clearance or a fixed ratio of 1 mg of protamine for every 100 IU of heparin required to establish anticoagulation pre-CPB. A planned, blinded interim analysis was undertaken after the recruitment of 50% of the study cohort. Following this, the randomisation ratio was adapted from 1:1 to 1:1.33 to increase recruitment to the superior arm while maintaining study power. At the conclusion of trial recruitment, we had randomised 121 patients to the intervention arm and 107 patients to the control arm. The primary endpoint was kaolin TEG r-time measured 3 minutes after protamine administration at the end of CPB. Secondary endpoints included ratio of kaolin TEG r-time pre-CPB to the same metric following protamine administration, requirement for allogeneic red cell transfusion, intercostal catheter drainage at 4 hours postoperatively, and the requirement for reoperation due to bleeding. The trial was listed on a clinical trial registry (ClinicalTrials.gov Identifier: NCT03532594). Participants were recruited between April 2018 and August 2019. Those in the intervention/model group had a shorter mean kaolin r-time (6.58 [SD 2.50] vs. 8.08 [SD 3.98] minutes; p = 0.0016) post-CPB. The post-protamine thromboelastogram of the model group was closer to pre-CPB parameters (median pre-CPB to post-protamine kaolin r-time ratio 0.96 [IQR 0.78-1.14] vs. 0.75 [IQR 0.57-0.99]; p < 0.001). We found no evidence of a difference in median mediastinal/pleural drainage at 4 hours postoperatively (140 [IQR 75-245] vs. 135 [IQR 94-222] mL; p = 0.85) or requirement (as a binary outcome) for packed red blood cell transfusion at 24 hours postoperatively (19 [15.8%] vs. 14 [13.1%] p = 0.69). Those in the model group had a lower median protamine dose (180 [IQR 160-210] vs. 280 [IQR 250-300] mg; p < 0.001). Important limitations of this study include an unblinded design and lack of generalisability to certain populations deliberately excluded from the study (specifically children, patients with a total body weight >120 kg, and patients requiring therapeutic hypothermia to <28°C). CONCLUSIONS: Using a mathematical model to guide protamine dosing in patients following CPB improved TEG r-time and reduced the dose administered relative to a fixed ratio. No differences were detected in postoperative mediastinal/pleural drainage or red blood cell transfusion requirement in our cohort of low-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov Unique identifier NCT03532594.
引用
- Miles LF, Burt C, Arrowsmith J, et al. Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial. PLoS Med. 2021. PMID: 34097705. doi:10.1371/journal.pmed.1003658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。